Skip to content
Mesothelioma.net
phone iconCall1-800-692-8608 chat icon Chat 24/7 Live Chat
Menu
  • Malignant Mesothelioma
    • About Mesothelioma
      • How to Survive Mesothelioma
      • 100 Questions & Answers about Mesothelioma (Free Book)
      • Symptoms
      • Diagnosis
      • Prognosis
      • Life Expectancy
    • Types
      • Pleural
      • Peritoneal
      • Epithelioid
      • Sarcomatoid
      • Biphasic
    • Stages
      • Stage 1
      • Stage 2
      • Stage 3
      • Stage 4
    • Additional Information
      • Causes
      • Asbestos and Its Dangers
      • Facts
      • Support
      • Financial Compensation
      • FREE Mesothelioma Packet
  • Treatment
    • Treatment Options
      • Surgery
      • Chemotherapy
      • Radiation Therapy
      • Multimodal Therapy
      • Medications
      • Palliative Treatment
    • Find Top Doctors
      • Doctors
      • Treatment Centers
      • Treatment & Doctors Near You
      • New Treatments
      • Care Providers
      • Clinical Trials
      • Costs
  • Asbestos Trusts
  • Compensation
  • Veteran Assistance
    • Mesothelioma and Veterans
      • VA Claims for Mesothelioma
      • Vietnam Veterans
    • Military Branches and Asbestos
      • Navy Veterans
      • Navy Ships
      • Marine Corps Veterans
      • Army Veterans
      • Air Force Veterans
      • U.S. Coast Guard
  • Surviving Mesothelioma
  • About Us / Contact
  • Home
  • ›
  • Malignant Mesothelioma
  • ›
  • Treatment
  • ›
  • Clinical Trials
  • ›
  • Chimeric Antigen Receptor (CAR) T-Cell
Page Updated: September 15, 2021

Chimeric Antigen Receptor (CAR) T-Cell Clinical Trial

Kyle J. Becker Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

FREE Mesothelioma Packet

Fact Checked

This page has been fact checked by a Doctor of Pharmacy who specializes in Oncology. Sources of information are listed at the bottom of the article.

FREE Mesothelioma Packet

We make every attempt to keep our information accurate and up-to-date.

Please Contact Us with any questions or comments.

The chimeric antigen receptor (CAR) T-cell clinical trials recruiting now represent a unique opportunity for patients who qualify to access an innovative medicine with great promise. This new type of immunotherapy modifies a patient’s immune system cells and has already shown good results with bone marrow and blood cancers. Trials are now recruiting peritoneal mesothelioma patients.

FREE Mesothelioma Packet

What is CAR T-Cell Therapy?

While new to mesothelioma treatment, chimeric antigen receptor (CAR) T-cell therapy is not entirely new. It has been used and is already approved for other cancer types, including leukemia in both children and adults.[1] It is also being tested in other cancers, including B-cell lymphoma, multiple myeloma, and acute myeloid leukemia.[2]

Treatment with CAR T-cell therapy requires several steps:[1]

  1. It begins with taking a patient’s blood and isolating T-cells. These are the cells in the immune system that are mostly responsible for attacking and killing unhealthy cells and pathogens in the body.
  2. The T-cells are then modified outside the body to begin producing a cancer-specific receptor molecule on their cell surfaces. This receptor is the CAR, or chimeric antigen receptor.The CAR has been created synthetically and is designed to target and attach to proteins on the surfaces of cancer cells.
  3. Once the T-cells have been modified with CAR, they are injected back into the patient’s bloodstream.
  4. They multiply, and the CAR molecules on all these T-cells quickly go to work attaching to and killing cancer cells.

CAR T-Cell Therapy for Peritoneal Mesothelioma

CAR T-cell therapy has been important in treating childhood leukemia. Oncologists and researchers are now testing the therapy with other types of cancers. Researchers often need to develop a new type of antigen because different cancers produce unique proteins on their cell surfaces.

MaxCyte, a cell-based medicine company, has produced a CAR T-cell therapy that it began testing for the treatment of ovarian cancer and peritoneal mesothelioma in 2018. The therapeutic candidate is known as MCY-M11.[3]

MCY-M11 is designed to target the cancer cell-expressed protein mesothelin, which is common in but not exclusive to mesotheliomas. A phase I trial ended and is no longer recruiting, but in 2020, MaxCyte announced the trial would continue.[4]

This is based on initial results that showed the feasibility of intraperitoneal delivery of the therapy. The results also showed the method was safe and that results for patients were promising and warranted further study.[5]

What makes MCY-M11 different from previous trials with CAR T-cell therapies is that the altered T-cells will not be given intravenously. Patients with peritoneal mesothelioma will have their T-cells injected directly into the abdominal cavity so that they will be placed closer to the site of action.

MaxCyte is also using a new type of system for altering T-cells faster, allowing for quicker turnaround times in treating patients.

CAR T-Cell Therapy for Pleural Mesothelioma

Studies are also just beginning that will use CAR T-cell therapy for pleural mesothelioma and lung cancer. The Abramson Cancer Center in Philadelphia recently received a large grant from the National Cancer Institute to develop a CAR T-cell therapy for these cancers.[6]

Like the MaxCyte product already being tested in peritoneal patients, this one will target mesothelin proteins. This phase I trial is recruiting qualifying patients with pleural mesothelioma.

Further, results from another phase I trial were reported showing both safety and efficacy with a mesothelin-targeting CAR T-cell therapy. Researchers observed no CAR T-cell-related safety events while witnessing promising improvement in the disease.[7]

Potential Side Effects

Participating in a clinical trial is important for patients with challenging cancers like mesothelioma. It gives patients a chance to access otherwise unavailable treatments that may work better than currently-approved therapies, and it allows them to help advance knowledge in treating that disease.

On the other hand, there are risks. Clinical trials are conducted not only to measure effectiveness but adverse effects as well.

Some of the side effects of CAR T-cell therapy can be troubling. The most common side effect is a condition called cytokine release syndrome (CRS). CRS causes severe, flu-like symptoms: chills, fever, fatigue, aches, generally lasting between three and twenty-one days. This response is caused by the rapid response of the immune system. In worst cases, multiple-organ failure can occur, so this is a medical emergency.[2]

Another potential side effect of CAR T-cell therapy is CAR T-cell-related encephalopathy syndrome, also known as immune effector cell-associated neurotoxicity syndrome (ICANS). About five days after treatment is initiated, some patients experience confusion, disorientation, and an inability to talk. This is also a medical emergency and should be reported to your provider.

CAR T-cell therapy holds a huge amount of promise for patients with all types of cancer. It is already helping children with leukemia and is now being tested on rarer but difficult cancers like mesothelioma. If you are interested in being a part of this study, your doctors can determine if you qualify and help get you enrolled.

Get Your FREE Mesothelioma Packet

Page Medically Reviewed and Edited by Kyle J. Becker, PharmD, MBA, BCOP

Kyle J. Becker

Kyle J. Becker, PharmD is certified by the Board of Pharmacy Specialties in Oncology Pharmacy. Dr. Becker earned his pharmacy degree from Shenandoah University and he currently serves as an oncology pharmacist at Parkview Cancer Institute.

Connect with Oncology Pharmacist Kyle J. Becker
References
  1. National Cancer Institute. (2019, July 30). CAR T Cells: Engineering Patient’s Immune Cells to Treat Their Cancers.
    Retrieved from: https://www.cancer.gov/about-cancer/treatment/research/car-t-cells
  2. DeMarco, C. (2018, February 26). 9 Things to Know about CAR T-Cell Therapy. MD Anderson Cancer Center.
    Retrieved from: https://www.mdanderson.org/publications/cancerwise/car-t-cell-therapy–9-things-to-know.h00-159221778.html
  3. MaxCyte. (2018, October 10). MaxCyte Commences Dosing in First Clinical Trial in Solid Tumors.
    Retrieved from: https://www.maxcyte.com/maxcyte-commences-dosing-in-first-clinical-trial-in-solid-tumors/
  4. MaxCyte. (2020, August 18). CARMA Cell Therapies™ Expands Phase I Trial of Anti-Mesothelin mRNA CAR-PBMC Cell Therapy MCY-M11.
    Retrieved from: https://maxcyte.com/carma-cell-therapies-expands-phase-i-trial-of-anti-mesothelin-mrna-car-pbmc-cell-therapy-mcy-m11/
  5. Annunziata, C.M., Ghobadi, A., Pennella, E.J., Vanas, J., Powell, C., Pavelova, M., Wagner, C., Kuo, M., Ullman, C.D., Hassan, R., and Thaker, P.H. (2020). Feasibility and Preliminary Safety and Efficacy of First-in-Human Intraperitoneal Delivery of MCY-M11, Anti-Human-Mesothelin CAR mRNA Transfected into Peripheral Blood Mononuclear Cells, for Ovarian Cancer and Malignant Peritoneal Mesothelioma. 38(Suppl15), 3014.
    Retrieved from: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.3014
  6. Penn Medicine News. (2018, October 22). Abramson Cancer Center Receives $10.7 Million to Study CAR T Cells in Solid Tumors.
    Retrieved from: https://www.pennmedicine.org/news/news-releases/2018/october/abramson-cancer-center-receives-10-million-to-study-car-t-cells-in-solid-tumors
  7. Adusumilli, P. (2019, March 31). CT036 – A phase I clinical trial of malignant pleural disease treated with regionally delivered autologous mesothelin-targeted CAR T cells: Safety and efficacy. AACR Annual Meeting 2019.
    Retrieved from: https://www.abstractsonline.com/pp8/#!/6812/presentation/9837
View All References

Site Navigation

Home
Malignant Mesothelioma
How to Survive Mesothelioma
100 Questions & Answers about Mesothelioma (Free Book)
Surviving Mesothelioma - Beating the Odds (Free Book)
FREE Mesothelioma Packet
Symptoms
Shortness of Breath
Cough
Night Sweats and Fever
Weight Loss
Pain
Difficulty Swallowing
Fatigue and Muscle Weakness
Gastrointestinal Complications
Diagnosis
Pathology
Staging
Stage 1
Stage 2
Stage 3
Stage 4
Metastasis and Progression
Brain Metastasis
Biopsy
miRview Test
Imaging
Fine Needle Aspiration Biopsy
Biomarkers and Blood Tests
Calretinin
Prognosis
Remission
Recurrence
Death Rate
Life Expectancy
Search for a Mesothelioma Cure
Types
Pleural
Peritoneal
Epithelioid
Sarcomatoid
Biphasic
Pericardial
Testicular
Cell Types
Rare Subtypes of Epithelial Mesothelioma
Deciduoid
Desmoplastic
Heterologous
Lymphohistiocytoid
Well-Differentiated Papillary
Tubulopapillary
Small Cell
Benign
Adenomatoid
Cystic
Unresectable
Localized
Idiopathic
Omental
Causes
Risk Factors
Latest Research
Genetic Components
Incidence
Latency Period
Mesothelioma Tumor
Health Insurance Coverage
Related Conditions
Immunodeficiency Disorders
Cholangiocarcinoma
Atelectasis
Pleural Plaques
Pleural Thickening
Pleural Effusion
Peritoneal Effusion (Ascites)
Mesothelial Hyperplasia and Proliferation
Pleuritis and Pleurisy
COPD
Anemia
Breast Cancer
Prevention
Complications
Misdiagnosis
Mesothelioma Commercial
Talcum Baby Powder
Lawyer
Lawsuits
Class Action Lawsuits
Settlements
Simian Virus 40
Differences From Other Cancers
Lung Cancer
Women
Children and Young Adults
Unknown Asbestos Exposure
Mesothelioma Without Asbestos
Cause of Death
Facts 
History
Awareness
Government and Research
National Mesothelioma Virtual Bank
Support
What to Expect
Living with Mesothelioma
Help a Loved One
Wrong and Right Things to Say
Caregivers
Financial Tips
Faith
Nutrition and Lifestyle
Intimacy
Mesothelioma and Fertility in Men
Fertility in Women with Mesothelioma
Emotional Health
COVID-19
Assisted Living
Hospice Care
Dying from Mesothelioma
Mourning
Coping Guide for Children
End-of-Life Decisions
Mesothelioma Awareness Day
Compensation for Victims
Lawyer
Alabama
Alaska
Arizona
Arkansas
California
Colorado
Connecticut
Delaware
Florida
Georgia
Hawaii
Idaho
Illinois
Indiana
Iowa
Kansas
Kentucky
Louisiana
Maine
Maryland
Massachusetts
Michigan
Minnesota
Mississippi
Missouri
Montana
Nebraska
Nevada
New Hampshire
New Jersey
New Mexico
New York
North Carolina
North Dakota
Ohio
Oklahoma
Oregon
Pennsylvania
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Vermont
Virginia
Washington D.C.
Washington
West Virginia
Wisconsin
Wyoming
Lawsuit
Settlements
Statute of Limitations
Treatment
Surgery
Side Effects
Pneumonectomy
Extrapleural Pneumonectomy
Lobectomy
Pleurectomy / Decortication
Post Op Care
Pleurectomy / Decortication vs. Extrapleural Pneumonectomy
Peritonectomy/Cytoreductive Surgery
Thoracotomy
Thoracoscopy
Pericardiectomy
Wedge Resection
Pleurodesis
Pericardiocentesis
Prosthetics
Paracentesis
Thoracentesis
Chemotherapy
Side Effects
Heated Intraperitoneal
Radiation Therapy
Side Effects
Intensity-Modulated
Brachytherapy
Proton Therapy
Image-Guided
External Beam
Three-Dimensional
Multimodal Therapy
New Treatments
SMART Protocol
Gene Therapy
Suicide Gene Therapy
Tumor-Based p53 Therapy
Cryotherapy for Mesothelioma
Tumor Treating Fields
MicroRNA
Palliative Treatment
Osteopathic
Doctors
Treatment Centers
Treatment & Doctors Near You
Mesothelioma Experts
Medications
Alimta (pemetrexed)
Adriamycin (doxorubicin)
Avastin (bevacizumab)
Cytoxan (cyclophosphamide)
Gemzar (gemcitabine)
Keytruda (Pembrolizumab)
Mitomycin
Navelbine (vinorelbine)
Opdivo (nivolumab) and Yervoy (ipilimumab)
Paraplatin (carboplatin)
Platinol (cisplatin)
Rheumatrex (methotrexate)
Sutent (sunitinib)
Taxol (paclitaxel)
Medical Marijuana
Care Providers
Clinical Trials
Anetumab Ravtansine
Atezolizumab
Chimeric Antigen Receptor (CAR) T-Cell
Durvalumab
Immunotoxin
Interferon Alfa-2b
Onconase (Ranpirnase)
VISTA Protein
Costs
Immunotherapy
Nanotechnology
Hyperbaric Oxygen Therapy
Home Medical Equipment
HMGB1 Secretion
Photodynamic Therapy
Targeted Therapies
Apoptosis
Stem Cells
Lung Transplantation
Body-Based Therapies
Alternative Therapies
Paul Kraus’s Method
Doctors and Treatment in Canada
Asbestos Trusts
Veterans
VA Claims for Mesothelioma
Vietnam Veterans
Military Branches and Asbestos
Navy Veterans
Navy Ships
Aircraft Carriers
Battleships
Destroyers
Asbestos on Navy Cruisers
Submarines
Amphibious Ships
Minesweepers
Auxiliary Ships
Marine Corps Veterans
Army Veterans
Air Force Veterans
U.S. Coast Guard
Asbestos
Occupational Exposure
Construction Workers
Shipyard Workers
Ship Repair
Steel Mill Workers
Industrial Workers
Boiler Workers
Power Plant Workers
Firefighters
Automotive Workers
Roofers
Oil Refineries
Mining
Transportation Industry
Machine Operators
Farmers and Agricultural Workers
Migrant Workers
Electrical Wiring
Labor Unions
Prisons
Chimneys, Furnaces, and Wood Stoves
Fiberglass Connection to Mesothelioma
Home Remodeling
School Buildings, Teachers
For Tech Students
Cancer
Lung Cancer
Pleural Based Cancers
Ovarian Cancer
Ovarian Cancer Lawsuits
Companies That Used Asbestos
Awareness and Education
Types of Asbestos & Mesothelioma Risk
Asbestosis
Interstitial Lung Disease
Smoking
Asbestos Ingestion
Exposure in a Natural Disaster
Ban Asbestos
Libby, Montana
Recycling Asbestos
Asbestos Detection
Legal Information by State
Canada
Mexico
United Kingdom
Australia
  • Malignant Mesothelioma
    • Treatment
    • Asbestos Trusts
  • Compensation
    • Veteran Assistance
    • Surviving Mesothelioma
  • FREE Mesothelioma Packet
    • Mesothelioma News
    • About Us / Contact
  • Privacy Policy
    • Disclaimer
    • Editorial Guidelines and Standards
This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information: verify here.
The information provided by Mesothelioma.net is not a substitute for professional medical advice, diagnosis or treatment.

Mesothelioma.net

5430 LBJ Freeway Suite 1200
Dallas, Texas 75240

Serving mesothelioma victims nationwide

1-800-692-8608

  • facebook
  • twitter
© 2022 Mesothelioma.net